Welcome to the
EVER Pharma Webinar
Platform.
We are happy to have you here!
Opening the vessel is not enough – Is Cerebrolysin the answer to improved longterm outcome after recanalization therapy?
The ongoing CERECAP (CErebrolysinRECanalizationAndPerfusion) pilot-trial series aims to answer the important question: Can a cytoprotective agent added to recanalization therapy improve longterm outcome and if yes, do specific patient groups benefits more than others? The panel consists of renowned stroke experts aiming to answer this important question and speak about their own clinical experiences using Cerebrolysin as add-on therapy as part of gold standard treatment. Duration: 60 minutes Languages: Webinar will be held in English language incl. subtitles if requested. Furthermore Russian and Ukrainian simultaneous translation will be offered.
Our Webinars
#stroke
Opening the vessel is not enough – Is Cerebrolysin the answer to improved longterm outcome after recanalization therapy?
On Demand
#tbi
Cerebrolysin’s evidence from TBI research – Treat early, reduce acute and post-acute complications
#tbi
Multidisciplinary Neurotrauma treatment - Panel Discussion about clinical reality and implementation strategies
#stroke
Treatment strategies for motor impaired stroke patients
#stroke
Cerebroprotective strategies in acute ischemic stroke - fiction or reality?
#stroke
The future of chronic stroke patient treatment - Interactive case discussions
#tbi
Neurorecovery - When evidence from the bench meets results at the bedside
#neurocognitive disorders
Treating cognitive decline after critical illnesses - A call to action
#stroke
New horizons improving gold standard therapy in acute stroke - Case discussions
#stroke
Get with the guidelines in post-stroke motor recovery - Expert panel discussion
#tbi
Evidence-based neurorecovery after stroke and TBI
#stroke